Otros idiomas Crossject Deutsche Boerse AG

Acciones

74C

FR0011716265

Mercado cerrado - Deutsche Boerse AG Otros sitios de cotización 08:02:11 16/07/2024			Varia. Cinco días.	Varia. 1 de enero.
1,826 ^EUR	+2,70 %		+16,16 %	-59,78 %

10/07	Crossject obtiene una financiación pública de 7 millones de euros para su nuevo producto de epinefrina	MT
10/07	Bolsa de Madrid: Mercados conectados a la corriente alterna

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Crossject participera à la 26ème Annual Global Investment Conference de H.C. Wainwright	15/07
Crossject to attend H.C. Wainwright 26th Annual Global Investment Conference	15/07
Markets Powered by Alternating Current	10/07
Crossject Gets EUR7 Million Public Funding for New Epinephrine Product	10/07
Crossject : financement public sécurisé jusqu'en 2026	10/07
En Direct des Marchés : BNP Paribas, TotalEnergies, Vallourec, Accenture, Boeing, Microsoft, Volkswagen...	10/07
Les marchés branchés sur courant alternatif	10/07
Borsa di Italia: Mercati collegati alla corrente alternata	10/07
Crossject obtient 6,9 millions d'euros de financement public dans le cadre du plan France 2030, pour accélérer le développement de ZENEO® Adrénaline	10/07
Crossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine	10/07
Crossject Receives EUR 6.9 Million Public Funding from the French Government, as Part of the France 2030 Innovation Plan, to Accelerate the Development of ZENEO Epinephrine	10/07
Crossject elaborates on ZEPIZURE potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	27/06
Crossject : Document AMF CP. 2024DD982992	26/06
Crossject : Document AMF CP. 2024DD982993	26/06
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude de référence RAMPART et de sa propre étude de bioéquivalence récemment publiée.	26/06
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study	26/06
Crossject : Document AMF CP. 2024DD982585	24/06
Crossject : Document AMF CP. 2024DD971458	17/06
Crossject SA Announces the Appointment of Dan Chiche as Chief Medical Officer North America	13/06
Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord	12/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Crossject Deutsche Boerse AG

Acciones

74C

FR0011716265

Otros idiomas

Filtros